Appln. Ser. No. 09/913,664 Atty. Docket No.: DLF-002.1P US

## BEST AVAILABLE COPY

## **AMENDED CLAIMS**

(deletions shown by strikethrough; additions underlined)

- (currently amended) A method for inhibiting rejection by a host mammal of donor tissue from another mammal which is to be transplanted into the host mammal, said method comprising

   (a) treating said viable donor tissue with an enzyme effective for temporarily ablating MHC
   Class I antigens from said donor tissue.
- (b) and transplanting said treated, viable donor tissue into said host mammal before MHC Class I antigens are re-expressed on the surface of said donor tissue, and
- (c) maintaining said viable donor tissue in said host.
- 2. (original) The method according to Claim 1, wherein said donor tissue is from a mammal that is the same species as said host mammal.
- 3. (original) The method according to Claim 1, wherein said donor tissue is from a mammal that is of a different species than said host mammal.
- 4. (original) The method according to Claim 1, wherein said host mammal is a human.
- 5. (original) The method according to Claim 1, wherein said tissue comprises blood cells, neurons, hepatocytes, cardiac cells, genetically modified cells, skin cells, precursor cells, endothelial cells, fibroblasts, myoblasts, islets of Langerhans cells, or bone marrow cells.
- 6. (original) The method according to Claim 1, wherein said tissue is an organ or part of an organ.
- 7. (original) The method according to Claim 6, wherein said organ is selected from the group consisting of skin, kidney, heart, pancreas, brain, and liver.
- 8. (original) The method according to Claim 1, wherein said donor tissue is additionally treated with a second enzyme effective to remove an antigenic surface structure from said donor tissue.
- 9. (original) The method according to Claim 1, wherein said enzyme is papain.





Appln. Ser. No. 09/913,664 Atty. Docket No.: DLF-002.1P US

- 10. (original) The method according to Claim 8, wherein said second enzyme is  $\alpha$ -galactosidase.
- 11. (original) The method according to Claim 8, wherein said donor tissue is treated with a combination of papain and  $\alpha$ -galactosidase.
- 12. (currently amended) A method for inhibiting rejection by a host mammal of donor tissue from another mammal which is to-be transplanted into the host mammal, said method comprising:
- (a) treating a first <u>viable</u> donor tissue with an enzyme effective for temporarily ablating MHC Class I antigens from said donor tissue,
- (b) transplanting said treated, viable donor tissue into said host mammal before MHC Class I antigens are re-expressed on the surface of said donor tissue, and
- (c) maintaining said viable donor tissue in said host mammal for a period sufficient for MHC Class I antigens to regenerate in cells of said treated donor tissue, and
- (d) transplanting a second donor tissue into said host mammal.
- 13. (currently amended) The A method according to Claim 12, wherein said first donor tissue is donor lymphocytes.
- 14. (currently amended) The A method according to Claim 12, wherein said second donor tissue is also treated prior to transplantation with an enzyme effective for removing MHC Class I antigens from said tissue.
- 15. (canceled)
- 16. (currently amended) The method according to Claim 12 Claim 15, wherein said first and second donor tissue is from a mammal that is the same species as said host mammal.
- 17. (currently amended) The method according to Claim 12 Claim 15, wherein said first and second donor tissue is from a mammal that is of a different species than said host mammal.
- 18. (currently amended) The method according to Claim 12 Claim 15, wherein said host mammal is a human.



- 19. (currently amended) The method according to <u>Claim 12 Claim 15</u>, wherein said <u>first and second donor</u> tissue <u>independently</u> comprises blood cells, neurons, hepatocytes, cardiac cells, genetically modified cells, skin cells, precursor cells, endothelial cells, fibroblasts, myoblasts, islets of Langerhans cells, or bone marrow cells.
- 20. (currently amended) The method according to Claim 12 Claim 15, wherein said first and second donor tissue is an organ or part of an organ.
- 21. (original) The method according to Claim 20, wherein said organ is selected from the group consisting of skin, kidney, heart, pancreas, brain, and liver.
- 22. (currently amended) The method according to Claim 1 Claim 15, wherein said donor tissue is treated with a solution of papain at 5-60 mg/ml for a period of 5 minutes to 24 hours.
- 23. (original) The method according to Claim 22, wherein said solution contains 20-28 mg/ml papain and said tissue is treated for 30-120 minutes.
- 24. (canceled)
- 25. (canceled)
- 26. (canceled)
- 27. (canceled)
- 28. (canceled)
- 29. (canceled)
- 30. (canceled)
- 31. (canceled)



- 32. (canceled)
- 33. (canceled)
- 34. (canceled)
- 35. (canceled)
- 36. (canceled)
- 37. (canceled)